1,721,184 research outputs found
Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia
No full textPh-Positive Acute Lymphoblastic Leukemia Until recently, Ph-positive ALL was very aggressive and difficult to treat. Current frontline therapy, based on tyrosine kinase inhibitors, glucocorticoids, and blinatumomab, has increased survival, with high-level clearance of measurable tumor cells
First-line dasatinib discontinuation in chronic myeloid leukaemia: another step towards an ``operational cure{''}
No full text
Measurable residual disease in chronic lymphocytic leukemia. Where do we stand?
No full textMeasurable residual disease in chronic lymphocytic leukemia. Where do we stand
Gene mutations in lenalidomide-treated CLL
No full textIn this issue of Blood, Takahashi et al provide evidence that cancer gene mutations in patients with chronic lymphocytic leukemia (CLL) have a prognostic role and significantly affect response to lenalidomide-based therapy.
Venetoclax: a chance for patients with chronic lymphocytic leukaemia previously treated with ibrutinib
Full text linkCommentwww.thelancet.com/oncology Vol 19 January 20187Biotheranostics, Exelixis, Bristol-Myers-Squibb, Janssen, Amgen, and Eisai; receives personal fees from NCCN (National Comprehensive Cancer Network); and receives institutional research funding and support from Boehringer-Ingelheim, Bayer, Onyx-Amgen, and Merck. TKC receives honoraria forAlligent, AstraZeneca, Bayer, Bristol-Myers Squibb, Cerulean Pharma, Eisai, Exelixis, Foundation Medicine, GlaxoSmithKline, Merck, Novartis, Peloton, Pfizer, Prometheus, and Roche/Genentech; institutional research funding and support from Pfizer, Exelixis, Bristol-Myers Squibb, Novartis, Peloton, AstraZeneca, Agensys, and TRACON. A-KAL declares no competing interests. 1Rosenberg JE, Hoffman-Censits J, Powles T, et al. Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 2016; 387: 1909–20.2Sharma P, Retz M, Siefker-Radtke A, et al. Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial. Lancet Oncol 2017; 18: 312–22.3Bellmunt J, de Wit R, Vaughn DJ, et al. Pembrolizumab as second-line therapy for advanced urothelial carcinoma. N Engl J Med 2017; 376: 1015–26.4Powles T, O’Donnell PH, Massard C, et al. Efficacy and safety of durvalumab in locally advanced or metastatic urothelial carcinoma: updated results from a phase 1/2 open-label study. JAMA Oncol 2017; 3: e172411. 5Patel MR, Ellerton J, Infante JR, et al. Avelumab in metastatic urothelial carcinoma after platinum failure (JAVELIN Solid Tumor): pooled results from two expansion cohorts of an open-label, phase 1 trial. Lancet Oncol2017; published online Dec 4. http://dx.doi.org/10.1016/S1470-2045(17)30900-2. 6Pond GR, Sonpavde G, Rosenberg JE, et al. Nomogram to assess benefit of new over historical agents as salvage therapy for metastatic urothelial carcinoma (mUC) in non-randomized trials: effect of atezolizumab on 12-month survival. J Clin Oncol 2017; 35: 346.7Boyerinas B, Jochems C, Fantini M, et al. Antibody-dependent cellular cytotoxicity activity of a novel anti-PD-L1 antibody avelumab (MSB0010718C) on human tumor cells. Cancer Immunol Res 2015; 3: 1148–57.8Martini DJ, Lalani AA, Bosse D, et al. Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. J Immunother Cancer 2017; 5: 66.9Petrylak DP, de Wit R, Chi KN, et al. Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): a randomised, double-blind, phase 3 trial. Lancet 2017; 390: 2266–77.10Powles T. IMvigor211: a phase III randomized study examining atezolizumab versus chemotherapy for platinum-treated advanced urothelial carcinoma. EACR-AACR-SIC Special Conference: Florence, Italy; June 24–27, 2017. Abstract 606.In recent years, biological and clinical research has identified several targeted agents that are changing the management of patients with chronic lymphocytic leukaemia. In clinical trials,1 the B-cell receptor inhibitor ibrutinib has led to durable responses and longer survival (overall and progression-free) than chemotherapy in patients with this disease. Ibrutinib is now largely used in clinical practice in patients with chromosome 17p deletions or TP53 mutations and relapsed or refractory chronic lymphocytic leukaemia
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
No full textThere are five tyrosine kinase inhibitors (TKIs) that are currently approved (in the European Union and the United States) for the treatment of chronic myeloid leukaemia (CML) in the chronic phase (CP) and each of them has its own efficacy and toxicity profile. Oral ponatinib (Iclusig((R))) is a third-generation TKI structurally designed to inhibit native BCR-ABL1 tyrosine kinase and several BCR-ABL1 mutants, including T315I. Ponatinib is now approved for patients with CML who are resistant or intolerant to prior TKI therapy (European Union) or for whom no other TKI therapy is indicated (United States). Despite achieving results in heavily treated patients, which led to its approval, the drug may induce cardiovascular events, requiring a careful baseline assessment of predisposing risk factors and specific management during treatment. Pharmacokinetic analysis has indicated the possibility of reducing the starting dose of ponatinib to 15 mg/day and preliminary data showed advantages in terms of safety while maintained its efficacy. This review summarizes the results achieved and drug-related side effects reported in all clinical trials and real-life experiences, testing ponatinib in patients with CP-CML. In addition, we focus on the appropriate use of ponatinib in clinical practice suggesting some useful recommendations on the proper management of this drug
Hemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulants
No full textHemorrhagic Complications in Patients Treated With Azacitidine and Direct Oral Anticoagulant
Insights into the optimal use of ponatinib in patients with chronic phase chronic myeloid leukaemia
No full textThere are five tyrosine kinase inhibitors (TKIs) that are currently
approved (in the European Union and the United States) for the treatment
of chronic myeloid leukaemia (CML) in the chronic phase (CP) and each of
them has its own efficacy and toxicity profile. Oral ponatinib
(Iclusig((R))) is a third-generation TKI structurally designed to
inhibit native BCR-ABL1 tyrosine kinase and several BCR-ABL1 mutants,
including T315I. Ponatinib is now approved for patients with CML who are
resistant or intolerant to prior TKI therapy (European Union) or for
whom no other TKI therapy is indicated (United States). Despite
achieving results in heavily treated patients, which led to its
approval, the drug may induce cardiovascular events, requiring a careful
baseline assessment of predisposing risk factors and specific management
during treatment. Pharmacokinetic analysis has indicated the possibility
of reducing the starting dose of ponatinib to 15 mg/day and preliminary
data showed advantages in terms of safety while maintained its efficacy.
This review summarizes the results achieved and drug-related side
effects reported in all clinical trials and real-life experiences,
testing ponatinib in patients with CP-CML. In addition, we focus on the
appropriate use of ponatinib in clinical practice suggesting some useful
recommendations on the proper management of this drug
A five-gene signature may associate with central nervous system dissemination in adult acute lymphoblastic leukemia
No full text- …
